Medtronic plc (MDT)
| Market Cap | 118.26B |
| Revenue (ttm) | 34.20B |
| Net Income (ttm) | 4.66B |
| Shares Out | 1.28B |
| EPS (ttm) | 3.62 |
| PE Ratio | 25.46 |
| Forward PE | 16.08 |
| Dividend | $2.84 (3.15%) |
| Ex-Dividend Date | Sep 26, 2025 |
| Volume | 7,519,489 |
| Open | 90.70 |
| Previous Close | 90.06 |
| Day's Range | 90.20 - 92.24 |
| 52-Week Range | 79.29 - 99.37 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 104.07 (+12.87%) |
| Earnings Date | Nov 18, 2025 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair produc... [Read more]
Financial Performance
In 2025, Medtronic's revenue was $33.54 billion, an increase of 3.62% compared to the previous year's $32.36 billion. Earnings were $4.66 billion, an increase of 26.82%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for MDT stock is "Buy." The 12-month stock price target is $104.07, which is an increase of 12.87% from the latest price.
News
Medtronic to announce financial results for its second quarter of fiscal year 2026
GALWAY, Ireland , Nov. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, November 18, 2025,...
Orchestra BioMed to Host Business Update Call on November 12, 2025
NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Best Dividend Aristocrats For November 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW...
U.S. Centers for Medicare & Medicaid Services finalizes National Coverage Determination for the Medtronic Symplicity Spyral™ renal denervation (RDN) system
Symplicity blood pressure procedure is now covered for qualifying Medicare patients GALWAY, Ireland , Oct. 28, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...
Three-year SPYRAL HTN-ON MED results show sustained, 18 mmHg office-based blood pressure reductions
Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplic...
Medtronic: A Revitalized Dividend Aristocrat To Buy Now
Medtronic's shares have sharply rallied over the last six months. The medtech giant's growth catalysts include a best-in-class product (Affera) in a fast-growing $11 billion space and a massive opport...
It's time to scoop up undervalued stocks in this critical sector of the economy
Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.
Medtronic Stock's $50 Billion Gift To Investors
In the last decade, Medtronic (MDT) stock has returned a notable $52 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let's look at some numbers and compare how this pa...
Medtronic plc - Special Call
Medtronic plc - Special Call Company Participants Ryan Weispfenning - VP & Head of Investor Relations Emily Elswick Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Nathan Tr...
Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions
TIME Best Inventions honors extraordinary innovations changing lives DUBLIN , Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Bra...
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart disease Orchestra BioMed and Medtronic (NYSE:...
Medtronic initiates U.S. IDE clinical study evaluating Hugo™ robotic-assisted surgery system for gynecological procedures
First procedures completed and enrollment underway in Embrace Gynecology study, furthering the company's progress to expand minimally invasive treatment options to patients in the United States GALWAY...
Medtronic Announces Closing of Public Offering of €1.5 Billion of Senior Notes
GALWAY, Ireland , Sept. 29, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public of...
Medtronic: FY26 Outlook Strengthened By New Product Launches
Medtronic (MDT) is undervalued, with strong organic growth and an 11% upside to a $105 target price, supporting a Buy rating. MDT's innovation pipeline, portfolio transformation, and spin-off of the d...
Medtronic plc (MDT) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Medtronic plc (NYSE:MDT) Bank of America Global Healthcare Conference 2025 September 24, 2025 9:10 AM EDT Company Participants Thierry Pieton - Executive VP & CFO Presentation Unknown Analyst We're g...
Medtronic secures FDA approval for the Altaviva™ device, a simple experience for treating urge urinary incontinence
The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland , Sept. 19, 2025 /PRNewswir...
Medtronic: Buy This Dividend Aristocrat While It's Good Value
Medtronic remains a Buy for long-term investors, offering steady growth, durable income, and an attractive valuation below historical averages. MDT delivered solid fiscal Q1 2026 results, with 8.4% re...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Medtronic Announces Pricing of €1.5 Billion of Senior Notes
GALWAY, Ireland , Sept. 15, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has priced an offering (the "Offe...
Medtronic initiates global pivotal study of cardiac pacing in a new patient population
Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have limited treatment options today GALW...
Medtronic Plc (MDT) Presents At Deutsche Bank Healthcare Summit Transcript
Medtronic plc (NYSE:MDT) Deutsche Bank Healthcare Summit September 10, 2025 12:00 PM EDT Company Participants Conference Call Participants Pito Chickering - Deutsche Bank AG, Research Division Presen...
Medtronic Plc (MDT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Medtronic plc (NYSE:MDT) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Thierry Pieton - Executive VP & CFO Conference Call Participants Pa...
Medtronic Plc (MDT) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Medtronic plc (NYSE:MDT) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Geoffrey Martha - Chairman of the Board & CEO Thierry Pieton - Executive...
Study of Medtronic Hugo™ robotic-assisted surgery system in hernia repair meets safety and effectiveness endpoints
First-ever investigational device exemption clinical study for robotic-assisted hernia repair in the U.S. presented at the American Hernia Society annual meeting GALWAY, Ireland and NASHVILLE, Tenn. ,...
FDA Clears MiniMed™ 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes
GALWAY, Ireland , Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones t...